IBI3002

Phase 2Small molecule

Innovent Biologics (Suzhou) Co. Ltd.

IBI3002 is one of 68 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisRecruiting

AsthmaRecruiting

Atopic DermatitisPhase 2

Recruiting

AsthmaPhase 1

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

IBI3002

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

3 4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Atopic Dermatitis

NCT07399067

Clinical

Trials by Indication[1]

Asthma3 trials

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT06947408·60 enrolled

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07015749·12 enrolled

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT06213844·52 enrolled

Atopic Dermatitis2 trials

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07015762·9 enrolled

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT07399067·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for IBI3002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBI3002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBI3002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.

IBI3002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Asthma3 trials

Atopic Dermatitis2 trials

References

Drug Info

Quick Facts

Related News